Pharmaceutical Technology
MARCH 29, 2023
In September 2021, Bristol Myers Squibb in-licensed the first programme, EVT8683, after the successful filing of an investigative new drug (IND) application with the Food and Drug Administration (FDA). This programme has now proceeded into a Phase I clinical trial.
pharmaphorum
NOVEMBER 21, 2022
The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the serious complications that can accompany advanced T1D. It also has an option on global marketing rights to the drug.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
FEBRUARY 8, 2021
Last year, Biocon Biologics and Mylan announced they’d be seeking interchangeable status for their long-acting insulin product Semglee , developed to be an alternative to Sanofi’s Lantus (insulin glargine). For example, ongoing patent litigation may dictate which indications are pursued for a biosimilar.
The Pharma Data
MAY 15, 2021
Description: Scientists have just discovered there’s a new, untapped reserve of insulin-producing cells hiding in the human body. The website’s content and the product for sale is based upon the author’s opinion and is provided solely on an “AS IS” and “AS AVAILABLE” basis.
Druggist
MAY 12, 2021
Celevac tablets were licensed as general sale list medicines (GSL), which means they could be sold in any retail outlet, including pharmacies, over the counter without a prescription. . Licensed use of Celevac tablets: Constipation. These advertised properties are similar to Celeva’s licensed use. What is Celevac?
The Pharma Data
MAY 4, 2021
The ban on the importation, manufacture, packing, sale, supply, possession, administration or use of unapproved COVID-19 vaccines therefore applies to all other vaccines, as well as to parallel imports of Comirnaty. TGA lifts suspension of Tandem t:slim X2 insulin pump, with conditions. TGA Notice , More. . CDSCO Notice. .
The Pharma Data
AUGUST 3, 2021
The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. million of revenue from sales of COVID-19 antibodies.
Expert insights. Personalized for you.
130 
Let's personalize your content